Chengdu Pukang Biotechnology Technology Co., Ltd. (hereinafter referred to as Pukang) was established in 2008. For more than ten years, it has been focusing on the research and development, production and sales of polypeptide modify side chains and single-molecule PEG (referred to as small molecule PEG) derivatives, has built small molecule PEG derivatives block library.

Pukang provides the best CDMO service to customers worldwide d on its R&D capabilities and state-of-the-art facilities. Pukang aims to be the best partner in realizing customer-tailored services through skilled professionals and top-notch facilities. We want to share our experience in developing and producing products in the fastest and highest quality manner through optimized routes with healthcare companies around the world.

Pukang has built a polypeptide long-acting modifier platform, which can not only provide hundreds of different types of peptide long-acting side chain molecules, but also provide high-quality long-acting side chain design services, quality research and CDE documents; Long-acting side chains can be used for GLP-1, GCP and anti-HIV drugs to improve half-life and enhance patient compliance. The company has developed and produced a series of multi-category, novel structures, high-quality long-acting polypeptide side chains for many companies around the world, mainly including aliphatic alkane series, MIPA series and cholesterol series products. Molecular block of long-acting peptide side chain helps customers to quickly realize the molecular screening and evaluation of innovative peptide drugs. In order to meet the needs of customers in the development of new drugs and commercialization stage, we have a 3,000-square-meter R&D a 2,000-square-meter pilot-scale laboratory and a 60,000-square-meter production that meets GMP requirements.

Pukang is deeply engaged in small molecule PEG derivatives, using single molecular weight PEG for drug delivery series, and establishing single molecular weight liposome molecular block which can use for nucleic acid drug siRNA delivery to improve drug stability and prolong half-life. Liposomes with a single molecular weight PEG can improve the quality of products, reduce the side effects caused by impurities, and reduce the difficulty of impurity research.